MYCN and neuroblastoma: MYCN-amplified neuroblastoma has been identified as particularly sensitive to ABT-199 treatment, and, in xenograft models, ABT-199 induced apoptosis and tumour regression in combination with the Aurora-A inhibitor MLN8237 [94].